FreeTheAI

Indutrade to Acquire Poland's Euromed Medical Solution in Bolt-On Deal

BullishLow impact
INDTSEK 269.20 −0.59%

Indutrade AB (OMXSTO:INDT) has signed an agreement to acquire all shares of Poland-based Euromed Medical Solution. The business generates annual sales of approximately 90 million Polish zlotys, equivalent to around 230 million Swedish kronor. Upon closing, the company will join Indutrade's Business Area Life Science division.

The acquisition marks Indutrade's 11th transaction in 2026, continuing its strategy of expanding market footprint and distribution capability in Central Europe through targeted bolt-on acquisitions. While the revenue contribution adds scale to the division, management expects the transaction to be marginally accretive to earnings per share.

Completion of the deal remains subject to approval from Polish competition authorities. Closing is anticipated in the fourth quarter of 2026, at which point the company will begin contributing to Indutrade's financial results.

Key points

  • Indutrade AB (OMXSTO:INDT) agreed to acquire 100% of Polish distributor Euromed Medical Solution.
  • Euromed generates annual revenue of approximately PLN 90 million (SEK 230 million).
  • The business will be integrated into Indutrade's Business Area Life Science division.
  • The transaction is expected to close in Q4 2026, subject to Polish competition approval.
  • The deal marks Indutrade's 11th bolt-on acquisition announced in 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What company is Indutrade acquiring in Poland?

Indutrade is acquiring all shares of Euromed Medical Solution, a Polish medical distribution business with annual sales of about 90 million Polish zlotys (SEK 230 million).

When is the Euromed Medical Solution deal expected to close?

The transaction is expected to close in the fourth quarter of 2026, pending clearance from Polish competition authorities.

How will the acquisition impact Indutrade's earnings?

The acquisition will join Indutrade's Business Area Life Science unit and is expected to be marginally accretive to earnings per share.